PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1681479
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1681479
Global Subdermal Contraceptive Implants Market Size Study, by Product (Etonogestrel Implant, Levonorgestrel Implant), by Distribution Channel (Hospitals, Gynecology Clinics, Community Health Care Centers, Others), and Regional Forecasts 2022-2032
The global subdermal contraceptive implants market was valued at approximately USD 1.12 billion in 2023 and is anticipated to grow at a CAGR of 7.61% from 2024 to 2032. The demand for long-acting reversible contraceptives (LARCs) has surged due to their high efficacy, low maintenance requirements, and long-term reliability compared to daily contraceptive pills or barrier methods. The increasing number of unintended pregnancies has driven greater adoption of these implants, as they provide a prolonged contraceptive effect with minimal user intervention. According to a 2022 report by the United Nations Population Fund (UNFPA), 121 million unintended pregnancies occur globally each year, reinforcing the urgent need for accessible and long-term contraceptive solutions.
Government and non-governmental organizations (NGOs) worldwide are actively promoting family planning initiatives, ensuring broader adoption of subdermal contraceptive implants, particularly in rural and underserved regions. For instance, in October 2023, India's Health and Family Welfare Ministry launched subdermal single-rod implants as part of an extensive family planning initiative. Furthermore, advancements in biocompatible materials, implant miniaturization, and simplified insertion/removal procedures are driving higher user adoption by reducing side effects and increasing comfort.
Technological innovations are enhancing the safety and usability of subdermal contraceptive implants, positioning them as a preferred choice for long-term birth control. The introduction of hormone-free and longer-lasting implants is expected to expand the product portfolio of major market players, catering to diverse consumer preferences. However, challenges such as limited healthcare access in developing regions, high procedural costs, and a shortage of trained professionals may hinder growth. Despite these challenges, strategic mergers, acquisitions, and partnerships among pharmaceutical companies, biotechnology firms, and healthcare providers are fostering market expansion and product innovation.
The North American market accounted for the largest share (64.91%) in 2023, primarily driven by high awareness levels, government-backed reimbursement programs, and increased adoption of advanced contraceptive technologies. Europe follows closely, with governments implementing favorable contraceptive policies and insurance coverage for long-acting reversible contraceptives. Meanwhile, the Asia-Pacific region is expected to experience the fastest growth rate over the forecast period, fueled by rising awareness, expanding healthcare infrastructure, and proactive government initiatives promoting family planning. The Latin American and Middle Eastern & African (MEA) markets are also poised for significant expansion due to improved accessibility and increasing contraceptive awareness campaigns.
Major Market Players Included in This Report:
- Merck & Co., Inc.
- Bayer AG
- Pfizer, Inc.
- Shanghai Dahua Pharmaceutical Co., Ltd.
- Gerresheimer AG
- Novartis AG
- SCHOTT
- Lilly
- Baxter
- BD (Becton, Dickinson, and Company)
- Theramex
- Contraline, Inc.
- ProMed Pharma LLC
- Dare Bioscience, Inc.
- Mithra Pharmaceuticals
The Detailed Segments and Sub-Segments of the Market are Explained Below:
By Product:
- Etonogestrel Implant
- Levonorgestrel Implant
By Distribution Channel:
- Hospitals
- Gynecology Clinics
- Community Health Care Centers
- Others
By Region:
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Kuwait
Years Considered for the Study Are as Follows:
- Historical Year - 2022
- Base Year - 2023
- Forecast Period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years (2022-2032).
- Annualized revenue projections and regional analysis for each market segment.
- Comprehensive geographical landscape analysis with country-level insights.
- Competitive landscape review, including leading market players.
- Strategic recommendations for future market approaches.
- Detailed analysis of market structure and competitive dynamics.
- In-depth demand-side and supply-side market assessments.
Table of Contents
Chapter 1. Global Subdermal Contraceptive Implants Market Executive Summary
- 1.1. Global Subdermal Contraceptive Implants Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Product
- 1.3.2. By Distribution Channel
- 1.4. Key Market Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Subdermal Contraceptive Implants Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory Frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Subdermal Contraceptive Implants Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Rising Demand for Long-Acting Reversible Contraceptives (LARCs)
- 3.1.2. Increasing Government Initiatives for Family Planning
- 3.1.3. Advancements in Implant Materials and Miniaturization
- 3.2. Market Challenges
- 3.2.1. Limited Availability of Trained Healthcare Professionals
- 3.2.2. High Initial Cost of Implant Procedures
- 3.3. Market Opportunities
- 3.3.1. Expansion in Emerging Markets with High Unintended Pregnancy Rates
- 3.3.2. Development of Non-Hormonal and Extended Duration Implants
Chapter 4. Global Subdermal Contraceptive Implants Market Industry Analysis
- 4.1. Porter's Five Forces Analysis
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Five Force Model
- 4.1.7. Porter's Five Forces Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political Factors
- 4.2.2. Economic Factors
- 4.2.3. Social Factors
- 4.2.4. Technological Factors
- 4.2.5. Environmental Factors
- 4.2.6. Legal Factors
- 4.3. Top Investment Opportunities
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends in the Market
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Subdermal Contraceptive Implants Market Size & Forecasts by Product (2022-2032)
- 5.1. Segment Dashboard
- 5.2. Global Subdermal Contraceptive Implants Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.2.1. Etonogestrel Implant
- 5.2.2. Levonorgestrel Implant
Chapter 6. Global Subdermal Contraceptive Implants Market Size & Forecasts by Distribution Channel (2022-2032)
- 6.1. Segment Dashboard
- 6.2. Global Subdermal Contraceptive Implants Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.2.1. Hospitals
- 6.2.2. Gynecology Clinics
- 6.2.3. Community Health Care Centers
- 6.2.4. Others
Chapter 7. Global Subdermal Contraceptive Implants Market Size & Forecasts by Region (2022-2032)
- 7.1. North America Subdermal Contraceptive Implants Market
- 7.1.1. U.S.
- 7.1.2. Canada
- 7.1.3. Mexico
- 7.2. Europe Subdermal Contraceptive Implants Market
- 7.2.1. UK
- 7.2.2. Germany
- 7.2.3. France
- 7.2.4. Italy
- 7.2.5. Spain
- 7.2.6. Denmark
- 7.2.7. Sweden
- 7.2.8. Norway
- 7.3. Asia-Pacific Subdermal Contraceptive Implants Market
- 7.3.1. China
- 7.3.2. India
- 7.3.3. Japan
- 7.3.4. Australia
- 7.3.5. South Korea
- 7.3.6. Thailand
- 7.4. Latin America Subdermal Contraceptive Implants Market
- 7.4.1. Brazil
- 7.4.2. Argentina
- 7.5. Middle East & Africa Subdermal Contraceptive Implants Market
- 7.5.1. Saudi Arabia
- 7.5.2. UAE
- 7.5.3. South Africa
- 7.5.4. Kuwait
Chapter 8. Competitive Intelligence
- 8.1. Key Company SWOT Analysis
- 8.1.1. Merck & Co., Inc.
- 8.1.2. Bayer AG
- 8.1.3. Pfizer, Inc.
- 8.2. Market Strategies of Leading Players
- 8.3. Company Profiles
- 8.3.1. Shanghai Dahua Pharmaceutical Co., Ltd.
- 8.3.2. BD (Becton, Dickinson, and Company)
- 8.3.3. Gerresheimer AG
- 8.3.4. Novartis AG
- 8.3.5. SCHOTT
- 8.3.6. Lilly
- 8.3.7. Baxter
- 8.3.8. Theramex
- 8.3.9. Contraline, Inc.
- 8.3.10. ProMed Pharma LLC
Chapter 9. Research Process
- 9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
- 9.2. Research Attributes
